

AUSTRALIAN PRODUCT INFORMATION – VAXIGRIP® (INFLUENZA VIRUS HAEMAGGLUTININ) SUSPENSION FOR INJECTION

1 NAME OF THE MEDICINE

Inactivated trivalent influenza vaccine, split virion (Influenza virus haemagglutinin)

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Vaxigrip is formulated to contain the following three influenza strains*:

Active Substance	Quantity (per 0.5 mL dose)
A/Missouri/11/2025 (H1N1)pdm09-like strain (A/Switzerland/6849/2025, IVR-278)	15 micrograms HA**
A/Singapore/GP20238/2024 (H3N2)-like strain (A/Singapore/GP20238/2024, IVR-277)	15 micrograms HA**
B/Austria/1359417/2021-like strain (B/Michigan/01/2021, wild type)	15 micrograms HA**

* propagated in fertilised hens' eggs from healthy chicken flocks

** haemagglutinin

The type and amount of viral antigens contained in Vaxigrip conform to the annual requirements of the Australian Influenza Vaccine Committee (AIVC) and the World Health Organisation (WHO) recommendations for the 2026 season.

For the full list of excipients, see Section [6.1 List of excipients](#).

3 PHARMACEUTICAL FORM

Suspension for injection in pre-filled syringe.

The vaccine, after shaking gently, is a colourless opalescent liquid.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Vaxigrip is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the one influenza B virus type contained in the vaccine for:

- active immunisation of adults, including pregnant women, and children from 6 months of age and older
- passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see Section 4.2 Dose and method of administration, Section 4.4 Special warnings and precautions for use, Section 4.6 Fertility, pregnancy and lactation and Section 5.1 Pharmacodynamic properties – clinical trials).

Vaxigrip should be given in accordance with the national recommendation as per the current Immunisation Handbook.

4.2 DOSE AND METHOD OF ADMINISTRATION

Given the antigenic variation in circulating influenza viruses and the duration of immunity provided by the vaccine, it is recommended to perform vaccination against influenza every year at the beginning of the risk period.

Individuals from 9 years of age: a single 0.5 mL injection.

Children from 6 months to 8 years of age:

- If the child has not previously been vaccinated: two 0.5 ml injections at least one month apart.
- If the child has been previously vaccinated: a single 0.5 ml injection.

Infants younger than 6 months of age:

No data are available regarding the safety and efficacy of Vaxigrip administration (active immunisation) in infants younger than 6 months of age.

Regarding passive protection, a single 0.5 ml injection given to pregnant women may protect infants from birth to less than 6 months of age; however not all these infants will be protected (see Section 5.1 Pharmacodynamic properties – clinical trials)

Method of administration

The vaccine should be given by intramuscular or deep subcutaneous injection.

The preferred site of administration is into the deltoid muscle in adults and children \geq 12 months of age. The preferred site for infants (6 months to < 12 months of age) is the anterolateral aspect of the thigh. The vaccine should be administered into healthy well developed muscle and should not be injected into the gluteal region where there may be a risk of local neural, vascular and tissue injury.

Shake before use to distribute uniformly the suspension before administration.

Parenteral drug products should be inspected visually for particulate matter and/or discolouration prior to administration whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.

The syringe is for single use only in one patient and must not be reused. Discard any remaining unused contents.

4.3 CONTRAINDICATIONS

Vaxigrip should not be given to individuals with a history of severe allergic reaction to any component of the vaccine (See Section 2 Qualitative and quantitative composition and Section 6.1 List of excipients). Vaxigrip should not be given to individuals with a history of severe allergic reaction after previous administration of Vaxigrip or a vaccine containing the same components.

Refer to Section 4.4 Special warnings and precautions for use for influenza vaccination for individuals with a known egg allergy.

Vaccination should be postponed in case of moderate or severe febrile or acute disease.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Vaxigrip should under no circumstances be administered intravenously.

Hypersensitivity

Prior to any vaccine injection, all known precautions should be taken to prevent hypersensitivity reactions. This includes a review of the individual's prior vaccination history with respect to possible hypersensitivity to the vaccine or similar vaccines. Adrenaline (epinephrine) injection (1:1000) and other appropriate agents used for the control of immediate allergic reactions must be available to treat unexpected reactions (e.g. anaphylaxis).

Individuals with egg allergy, including a history of anaphylaxis, can be safely vaccinated with influenza vaccines. Refer to the current Immunisation Handbook for guidance on the use of influenza vaccines in individuals with egg allergy.

Vaxigrip may contain traces of formaldehyde and octoxinol 9 which are used during vaccine production, caution should be exercised when the vaccine is administered to individuals with hypersensitivity to either one of these products.

As each dose may contain undetectable traces of neomycin, which is used during vaccine production, caution should be exercised when the vaccine is administered to individuals with hypersensitivity to this antibiotic (and other antibiotics of the same class).

Neurological Disorders

Patients with a history of Guillain-Barré Syndrome (GBS) with an onset related in time to influenza vaccination may be at increased risk of again developing GBS, but whether vaccination specifically might increase the risk for recurrence is unknown. Because patients with a history of GBS have an increased likelihood of again developing the syndrome, the chance of them coincidentally developing the syndrome following influenza vaccination may be higher than in individuals with no history of GBS. If GBS has occurred within 6 weeks following previous influenza vaccination, the decision to give Vaxigrip should be based on careful consideration of the potential benefits and risks.

Immunosuppressive Treatments or Conditions

If Vaxigrip is administered to immunocompromised individuals, whether due to genetic defect, immunodeficiency disease, or immunosuppressive therapy, they may have a reduced immune response to vaccination. For current recommendation, refer to the current Immunisation Handbook.

Protection

As with any vaccine, vaccination with Vaxigrip may not protect 100% of recipients.

Regarding passive protection, not all infants younger than 6 months of age born to women vaccinated during pregnancy will be protected (see Section 5.1 Pharmacodynamic properties – clinical trials)

Influenza virus is remarkably unpredictable in that significant antigenic changes may occur from time to time. It is known that influenza vaccines, as now constituted, are not effective against all possible strains of influenza virus. Protection is limited to those strains of virus from which the vaccine is prepared or to closely related strains.

Bleeding Disorders

As with other vaccines administered intramuscularly, the vaccine should be administered with caution to individuals with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these individuals.

Syncope

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. Procedures should be in place to prevent injury from fainting and manage syncopal reactions.

Use in the elderly

Annual influenza vaccination is recommended for individuals 65 years of age and over.

Paediatric use

Infants younger than 6 months of age:

No data are available regarding the safety and efficacy of Vaxigrip administration (active immunisation) in infants younger than 6 months of age. Regarding passive protection, one 0.5 ml dose given to pregnant women may protect infants from birth to less than 6 months of age; however not all these infants will be protected (see Section 4.2 Dose and method of administration and Section 5.1 Pharmacodynamic properties – clinical trials)

Effects on laboratory tests

Interference of Vaxigrip with laboratory and/or diagnostic tests has not been studied.

Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique can be used to disprove these results. The transient false positive reactions could be due to IgM response by the vaccine.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Clinical data showing that Vaxigrip can be administered concomitantly with other vaccines are available for the following vaccines: 23-valent pneumococcal polysaccharide vaccine in elderly, dTpa-IPV (diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine) in adults aged ≥ 60 years, and zoster vaccine in adults aged 50 and older.

Vaxigrip can be given at the same time as other vaccines.

Separate injection sites and separate syringes should be used in case of concomitant administration.

Individuals deficient in producing antibodies due to immunosuppressive therapy may have a reduced immune response to vaccination.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no fertility data available in humans. One animal study with Vaxigrip Tetra (Quadrivalent Influenza Vaccine (QIV)) did not indicate harmful effects on female fertility in rabbits.

Use in pregnancy (Category A)

Animal reproductive studies have not been conducted with Vaxigrip. One development and reproductive study conducted in rabbits with Vaxigrip Tetra (QIV) can be extrapolated to Vaxigrip: this study did not indicate direct or indirect harmful effects with respect to pregnancy, embryo-fetal development or early post-natal development.

Data from studies involving large numbers of women (> 80,000) vaccinated during pregnancy with inactivated influenza vaccines do not indicate any adverse fetal and maternal outcomes attributable to the vaccine.

Data from four clinical studies conducted with Vaxigrip administered to pregnant women during the second and third trimesters (more than 5,000 exposed pregnancies and more than 5,000 live births, followed up to approximately 6 months postpartum) did not indicate any adverse fetal, newborn, infant, or maternal outcomes attributable to the vaccine.

In three of these clinical studies conducted in South Africa and Nepal, there were no significant differences between the Vaxigrip and placebo groups with regards to fetal, newborn, infant, or maternal outcomes (including miscarriage, stillbirth, premature birth, low birth weight).

In the fourth study conducted in Mali, there were no significant differences between the Vaxigrip and control vaccine (quadrivalent meningococcal conjugate vaccine) groups with regards to prematurity rate, stillbirth rate, or rate of low birth weight/small for gestational age.

Data from a clinical study conducted in Finland with Vaxigrip and Vaxigrip Tetra (QIV) administered in pregnant women during the second or third trimester (116 exposed pregnancies and 119 live births for Vaxigrip, 230 exposed pregnancies and 231 live births for Vaxigrip Tetra (QIV)) did not indicate any adverse fetal or maternal outcomes attributable to the vaccine.

Vaxigrip can be administered in all stages of pregnancy based on the safety data from clinical studies and post-marketing experience. Larger datasets on safety of inactivated influenza vaccines are available for the second and third trimesters than for the first trimester. Data from worldwide use of inactivated influenza vaccines, including Vaxigrip and Vaxigrip Tetra (QIV), do not indicate any adverse fetal and maternal outcomes attributable to the vaccine. Because of the known adverse consequences of influenza infection in pregnant women, health authorities recommend vaccination of pregnant women.

Use in lactation

There are no data on the effect of the vaccine in breastfed newborns/infants of women vaccinated with Vaxigrip during breastfeeding period. Based on experience with inactivated influenza vaccines, Vaxigrip may be used during breastfeeding.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

No studies on the effects on the ability to drive and use machines have been performed.

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Within each system organ class, the adverse events are ranked under headings of frequency, using the following convention:

Very common	$\geq 1/10$ ($\geq 10\%$)
Common	$\geq 1/100$ and $< 1/10$ ($\geq 1\%$ and $< 10\%$)

Uncommon	$\geq 1/1000$ and $< 1/100$ ($\geq 0.1\%$ and $< 1\%$)
Rare	$\geq 1/10.000$ and $< 1/1000$ ($\geq 0.01\%$ and $< 0.1\%$)
Very rare	$< 1/10.000$ ($< 0.01\%$)
Not known	Cannot be estimated from available data

Clinical Trial Data

The safety profile of Vaxigrip is based on integrated safety analysis from clinical studies conducted with Vaxigrip and Vaxigrip Tetra (QIV). A total number of 17,917 individuals received an intramuscular or a subcutaneous injection of Vaxigrip or Vaxigrip Tetra (QIV).

Most reactions usually occurred within the first 3 days following vaccination and resolved spontaneously within 1 to 3 days after onset. The intensity of most of these reactions was mild to moderate.

The most frequently reported adverse reaction after vaccination was injection site pain in all populations including children from 6 to 35 months of age.

In the subpopulation of children less than 24 months of age, irritability (34.9%) was the most frequently reported adverse reaction.

In the subpopulation of children from 24 to 35 months of age, malaise (26.8%) was the most frequently reported adverse reaction.

Adults and the elderly

A total of 8,104 adults from 18 to 60 years and 5,860 adults over 60 years of age received one 0.5 mL dose of Vaxigrip or of Vaxigrip Tetra (QIV) during clinical studies.

In adults, the most frequently reported adverse reactions after vaccination were injection site pain (52.8%), headache (27.8%), myalgia (23.0%), and malaise (19.2%).

In the elderly, the most frequently reported adverse reactions after vaccination were injection site pain (25.8%), headache (15.6%), and myalgia (13.9%).

Overall, adverse reactions were generally less frequent in the elderly than in adults and children.

Table 1 - Frequency of solicited adverse reactions within 7 days after vaccination with Vaxigrip or Vaxigrip Tetra (QIV) in adults and elderly over 60 years of age

Adverse reactions	Adult 18-60 Years (N=8,104)		Elderly > 60 Years (N=5,860)	
	TIV (N=5,064)	QIV (N=3,040)	TIV (N=4,468)	QIV (N=1,392)
Nervous system disorders				
Headache	23.6% (Very common)	27.8% (Very common)	12.6% (Very common)	15.6% (Very common)
Musculoskeletal and connective tissue disorders				
Myalgia	22.7% (Very common)	23.0% (Very common)	11.2% (Very common)	13.9% (Very common)
General Disorders and Administration Site Conditions				
<i>Local reactions</i>				
Injection site pain	45.5% (Very common)	52.8% (Very common)	18.7% (Very common)	25.8% (Very common)
Injection site erythema	7.5% (Common)	7.6% (Common)	7.3% (Common)	7.0% (Common)
Injection site induration	4.7% (Common)	5.7% (Common)	2.9% (Common)	3.0% (Common)
Injection site swelling	3.8% (Common)	5.9% (Common)	2.9% (Common)	3.5% (Common)
Injection site ecchymosis	0.9% (Uncommon)	0.9% (Uncommon)	0.9% (Uncommon)	0.4% (Uncommon)
<i>Systemic reactions</i>				
Fever (oral temperature > 38°C)	1.0% (Common)	1.3% (Common)	0.7% (Uncommon)	0.9% (Uncommon)
Shivering	6.6% (Common)	6.2% (Common)	4.5% (Common)	4.3% (Common)
Malaise	11.9% (Very common)	19.2% (Very common)	7.7% (Common)	9.3% (Common)

Table 2 - Frequency of unsolicited adverse reactions within 1 month* after vaccination with Vaxigrip or Vaxigrip Tetra in adults and elderly over 60 years of age

Adverse reactions	Adult 18-60 Years (N=8,104)		Elderly > 60 Years (N=5,860)	
	TIV (N=5,064)	QIV (N=3,040)	TIV (N=4,468)	QIV (N=1,392)
Blood and lymphatic system disorders				
Lymphadenopathy	0.2% (Uncommon)	0.1% (Uncommon)	<0.1% (Rare)	0%
Immune system disorders				
Hypersensitivity	0.6% (Uncommon)	<0.1% (Rare)	0%	0%
Urticaria	0.3% (Uncommon)	<0.1% (Rare)	0%	0%
Angioedema	0%	<0.1% (Rare)	0%	0%
Dermatitis allergic	0%	<0.1% (Rare)	0%	0%

Adverse reactions	Adult 18-60 Years (N=8,104)		Elderly > 60 Years (N=5,860)	
	TIV (N=5,064)	QIV (N=3,040)	TIV (N=4,468)	QIV (N=1,392)
Dermatitis atopic	0.3% (Uncommon)	0%	0%	0%
Erythema	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)
Pruritus	<0.1% (Rare)	<0.1% (Rare)	0%	0.1% (Uncommon)
Pruritus generalized	0%	<0.1% (Rare)	0%	0%
Rash	<0.1% (Rare)	0%	<0.1% (Rare)	0%
Swelling face	<0.1% (Rare)	0%	<0.1% (Rare)	<0.1% (Rare)
Throat irritation	<0.1% (Rare)	0%	<0.1% (Rare)	0%
Asthma	0.3% (Uncommon)	0%	<0.1% (Rare)	0%
Dyspnea	<0.1% (Rare)	<0.1% (Rare)	0%	0%
Rhinitis allergic	0.6% (Uncommon)	0%	0%	0%
Rhinorrhea	0.1% (Uncommon)	0%	<0.1% (Rare)	0%
Sneezing	<0.1% (Rare)	0%	<0.1% (Rare)	0%
Nasal obstruction	<0.1% (Rare)	0%	0%	0%
Upper respiratory tract congestion	<0.1% (Rare)	0%	0%	0%
Oropharyngeal pain	0.8% (Uncommon)	0%	0.2% (Uncommon)	0%
Oral mucosal eruption	0%	0%	<0.1% (Rare)	0%
Paresthesia oral	0%	0%	<0.1% (Rare)	0%
Flushing	0%	0%	<0.1% (Rare)	0%
Hot flush	0%	0%	0%	0.1% (Uncommon)
Conjunctivitis allergic	0.3% (Uncommon)	0%	0%	0%
Ocular hyperemia	<0.1% (Rare)	0%	0%	0%
Metabolism and nutrition disorders				
Decreased appetite	<0.1% (Rare)	0%	<0.1% (Rare)	0%
Nervous system disorders				
Paresthesia	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)
Hypoesthesia	<0.1% (Rare)	0%	0%	0%
Somnolence	<0.1% (Rare)	<0.1% (Rare)	0.1% (Uncommon)	<0.1% (Rare)
Dizziness	<0.1% (Rare)	<0.1% (Rare)	0.1% (Uncommon)	0.1% (Uncommon)
Gastrointestinal disorders				
Diarrhea	0.1% (Uncommon)	0.1%	0.1% (Uncommon)	0.1% (Uncommon)
Nausea	0.2% (Uncommon)	0.1%	0.1% (Uncommon)	<0.1% (Rare)
Vomiting	<0.1% (Rare)	0%	<0.1% (Rare)	0%
Abdominal pain	<0.1% (Rare)	0%	0%	0%

Adverse reactions	Adult 18-60 Years (N=8,104)		Elderly > 60 Years (N=5,860)	
	TIV (N=5,064)	QIV (N=3,040)	TIV (N=4,468)	QIV (N=1,392)
Skin and subcutaneous tissue disorders				
Hyperhidrosis	0.1% (Uncommon)	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)
Musculoskeletal and connective tissue disorders				
Arthralgia	0.1% (Uncommon)	<0.1% (Rare)	<0.1% (Rare)	0%
General Disorders and Administration Site Conditions				
<i>Local reactions</i>				
Injection site warmth	0.2% (Uncommon)	0.2% (Uncommon)	<0.1% (Rare)	0.1% (Uncommon)
Injection site discomfort	0.1% (Uncommon)	<0.1% (Rare)	0.1% (Uncommon)	0%
Injection site pruritus	0.2% (Uncommon)	0.8% (Uncommon)	0.3% (Uncommon)	0.8% (Uncommon)
Injection site hypersensitivity	<0.1% (Rare)	0%	0%	0%
Injection site exfoliation	0%	0%	<0.1% (Rare)	0%
<i>Systemic reactions</i>				
Asthenia	0.5% (Uncommon)	<0.1% (Rare)	<0.1% (Rare)	<0.1% (Rare)
Fatigue	0.2% (Uncommon)	0.4% (Uncommon)	0.3% (Uncommon)	0.2% (Uncommon)
Flu-like symptoms	<0.1% (Rare)	<0.1% (Rare)	0%	<0.1% (Rare)

* 1 month for TIV; 21 days for QIV

Paediatric population

The safety profile presented below is based on data from 725 children from 9 to 17 years of age who received one dose of Vaxigrip or Vaxigrip Tetra (QIV) and from 1247 children from 3 to 8 years of age who received one or two doses of Vaxigrip or Vaxigrip Tetra (QIV) depending on their influenza vaccination history.

In children/adolescents from 9 to 17 years of age, the most frequently reported adverse reactions after vaccination were injection site pain (65.3%), myalgia (29.1%), headache (28.6%), malaise (20.3%), shivering (13.0%), injection site erythema (11.7%) and injection site swelling (11.4%).

In children from 3 to 8 years of age, the most frequently reported adverse reactions after any vaccination were injection site pain (59.1%), malaise (30.7%), injection site erythema (30.3%), myalgia (28.5%), headache (25.7%), injection site swelling (22.1%), injection site induration (17.6%), and shivering (11.2%).

The safety profile was similar after the first and the second injections.

Table 3 and **Table 4** summarise the frequencies of solicited and unsolicited adverse reactions that were recorded after any vaccination in children and adolescents from 3 years to 17 years of age.

Table 3 - Frequency of solicited adverse reactions within 7 days after any[#] vaccination with Vaxigrip or Vaxigrip Tetra in children and adolescents from 3 years to 17 years of age

Adverse reactions	Children and adolescents 9-17 years (N=725)		Children 3-8 years (N=1247)	
	TIV (N=296)	QIV (N=429)	TIV (N=363)	QIV (N=884)
Nervous system disorders				
Headache	28.6% (Very common)	24.7% (Very common)	19.9% (Very common)	25.7% (Very common)
Musculoskeletal and connective tissue disorders				
Myalgia	27.6% (Very common)	29.1% (Very common)	25.0% (Very common)	28.5% (Very common)
General Disorders and Administration Site Conditions				
<i>Local reactions</i>				
Injection site pain	65.3% (Very common)	54.5% (Very common)	59.1% (Very common)	56.5% (Very common)
Injection site erythema	11.7% (Very common)	9.8% (Common)	30.3% (Very common)	20.4% (Very common)
Injection site swelling	11.4% (Very common)	10.7% (Very common)	22.1% (Very common)	20.5% (Very common)
Injection site induration	9.7% (Common)	6.8% (Common)	17.6% (Very common)	16.4% (Very common)
Injection site ecchymosis	0.8% (Uncommon)	1.6% (Common)	7.4% (Common)	5.8% (Common)
<i>Systemic reactions</i>				
Fever	4.5% (Common)	2.3% (Common)	8.6% (Common)	8.4% (Common)
Shivering	13.0% (Very common)	3.7% (Common)	9.2% (Common)	11.2% (Very common)
Malaise	14.6% (Very common)	20.3% (Very common)	22.3% (Very common)	30.7% (Very common)

One dose for children from 9 to 17 years of age and one or two doses in children from 3 to 8 years of age

Table 4 - Frequency of unsolicited adverse reactions within 1 month[§] after any[#] vaccination with Vaxigrip or Vaxigrip Tetra (QIV) in children and adolescents from 3 years to 17 years of age

Adverse reactions	Children and adolescents 9-17 years (N=725)		Children 3-8 years (N=1247)	
	TIV (N=296)	QIV (N=429)	TIV (N=363)	QIV (N=884)
Blood and lymphatic system disorders				
Lymphadenopathy	0%	0%	0.3% (Uncommon)	0%
Thrombocytopenia	0%	0%	0%	0.1% (Uncommon)
Immune System Disorders				
Urticaria	0.3% (Uncommon)	0%	0.6% (Uncommon)	0%
Rash	0.3% (Uncommon)	0%	0.3% (Uncommon)	0%
Pruritus	0%	0%	0.3% (Uncommon)	0%
Oropharyngeal pain	0%	0%	0.6% (Uncommon)	0%
Psychiatric disorders				
Restlessness	0%	0%	0%	0.2% (Uncommon)

Adverse reactions	Children and adolescents 9-17 years (N=725)		Children 3-8 years (N=1247)	
	TIV (N=296)	QIV (N=429)	TIV (N=363)	QIV (N=884)
Moaning	0%	0%	0%	0.1% (Uncommon)
Nervous system Disorders				
Dizziness	0.3% (Uncommon)	0%	0%	0.2% (Uncommon)
Gastrointestinal Disorders				
Diarrhea	0%	0.2% (Uncommon)	0.8% (Uncommon)	0.5% (Uncommon)
Abdominal pain	0%	0%	0.8% (Uncommon)	0.1% (Uncommon)
Vomiting	0%	0%	0%	0.2% (Uncommon)
Musculoskeletal And Connective Tissue Disorders				
Arthralgia	0%	0%	0%	0.1% (Uncommon)
General Disorders and Administration Site Conditions				
<i>Local reactions</i>				
Injection site discomfort	0.3% (Uncommon)	0%	0%	0%
Injection site warmth	0.7% (Uncommon)	0%	0%	0.3% (Uncommon)
Injection site pruritus	0.7% (Uncommon)	0.2% (Uncommon)	0.3% (Uncommon)	0%
<i>Systemic reactions</i>				
Fatigue	0.3% (Uncommon)	0%	0.3% (Uncommon)	0.6% (Uncommon)
Asthenia	0.3% (Uncommon)	0%	0%	0%
Crying	0%	0%	0.3% (Uncommon)	0%

§ 1 month for TIV; 21 days for QIV in children from 9 to 17 years of age; 28 days for QIV in children from 3 to 8 years of age

One dose for children from 9 to 17 years of age and one or two doses in children from 3 to 8 years of age

The safety profile presented below is based on data from 1981 children from 6 to 35 months of age who received one or two doses of Vaxigrip or Vaxigrip Tetra (QIV) depending on their immunisation history.

In children from 6 to 35 months of age, the most frequently reported adverse reactions after any vaccination were injection site pain/tenderness (29.4%), fever (20.4%) and injection site erythema (17.2%).

In the subpopulation of children from 6 to 23 months of age, the most frequently reported adverse reactions after any vaccination were irritability (34.9%), crying abnormal (31.9%), appetite lost (28.9%), drowsiness (19.2%) and vomiting (17.0%).

In the subpopulation of children from 24 to 35 months of age, the most frequently reported adverse reactions after any vaccination were malaise (26.8%), myalgia (14.5%), and headache (11.9%).

The safety profile was similar after the first and the second injections with a trend of lower incidence of adverse reactions after the second injection compared to the first one.

Table 5 and **Table 6** summarise the frequencies of solicited and unsolicited adverse reactions that were recorded after any vaccination in children from 6 to 35 months of age.

Table 5 - Frequency of solicited adverse reactions within 7 days after any vaccination with Vaxigrip or Vaxigrip Tetra (QIV) in children from 6 to 35 months of age

Adverse reactions	Children 6-35 months (N=1981)	
	TIV (N=367)	QIV (N=1614)
Metabolism and nutrition disorders		
Decreased appetite ¥	27.9% (Very common)	28.9% (Very common)
Psychiatric system disorders		
Irritability*	34.9% (Very common)	32.3% (Very common)
Crying abnormal*‡	31.9% (Very common)	21.7% (Very common)
Nervous system disorders		
Headache*	10.6% (Very common)	11.9% (Very common)
Drowsiness*	19.2% (Very common)	13.9% (Very common)
Gastrointestinal disorder		
Vomiting*	17.0% (Very common)	16.1% (Very common)
Musculoskeletal and connective tissue disorders		
Myalgia*	14.5% (Very common)	11.6% (Very common)
General Disorders and Administration Site Conditions		
<i>Local reactions</i>		
Injection site pain/tenderness	29.4% (Very common)	26.8% (Very common)
Injection site erythema	8.9% (Common)	17.2% (Very common)
Injection site swelling	3.9% (Common)	7.6% (Common)
Injection site induration	6.7% (Common)	9.1% (Common)
Injection site ecchymosis	4.2% (Common)	4.2% (Common)
<i>Systemic reactions</i>		
Fever	20.2% (Very common)	20.4% (Very common)
Shivering*	9.9% (Common)	5.6% (Common)
Malaise	25.2% (Very common)	26.8% (Very common)

¥ Adverse reactions only recorded in children from 6 to 23 months of age (N=234 for TIV; N= 1003 for QIV).

* Adverse reactions only recorded in children from 24 to 35 months of age (N=133 for TIV; N=611 for QIV).

Table 6 - Frequency of unsolicited adverse reactions within 1 month[§] after any vaccination with Vaxigrip or Vaxigrip Tetra (QIV) in children from 6 months to 35 months of age

Adverse reactions	Children 6-35 months	
	TIV (N=367)	QIV (N=1981)
Immune system Disorders		
Hypersensitivity	0%	0.1% (Uncommon)
Rash papular	0%	<0.1% (Rare)
Pruritus generalized	0%	<0.1% (Rare)
Psychiatric system disorders		
Irritability [*]	0%	<0.1% (Rare)
Gastrointestinal Disorders		
Diarrhea	0.5% (Uncommon)	0.5% (Uncommon)
Vomiting [*]	0%	0.2% (Uncommon)
Musculoskeletal And Connective Tissue Disorders		
Myalgia [‡]	0%	<0.1% (Rare)
General Disorders and Administration Site Conditions		
<i>Local reactions</i>		
Injection site pruritus	0%	<0.1% (Rare)
Injection site rash	0%	<0.1% (Rare)
<i>Systemic reactions</i>		
Influenza like illness	0%	<0.1% (Rare)
Malaise [‡]	0%	<0.1% (Rare)

[§] 1 month for TIV; 28 days for QIV

^{*} In children ≥ 24 months of age

[‡] In children < 24 months of age

Other special populations

Although only a limited number of subjects with co-morbidities were enrolled, studies conducted in renal transplant patients or asthmatic patients showed no major differences in terms of safety profile of Vaxigrip in these populations. The safety profile of Vaxigrip Tetra (QIV) observed in a limited number of subjects with co-morbidities enrolled in the clinical studies does not differ from the one observed in the overall population.

Pregnant women:

In clinical studies conducted in pregnant women in South Africa and Mali with Vaxigrip (see Section 4.6 Fertility, Pregnancy and Lactation and Section 5.1 Pharmacodynamic properties – clinical trials), frequencies of local and systemic solicited reactions reported within 7 days following administration of Vaxigrip, were generally consistent with those reported for the adult population

during clinical studies. In the study conducted in South Africa, local reactions were more frequent in the Vaxigrip group than in the placebo group in both HIV-negative and HIV-positive cohorts. There were no other significant differences in solicited reactions between Vaxigrip and placebo groups in both cohorts.

In one clinical study conducted in pregnant women in Finland with Vaxigrip and Vaxigrip Tetra (QIV) (see Section 4.6 Fertility, pregnancy and lactation and Section 5.1 Pharmacodynamic properties – Immunogenicity of Vaxigrip), frequencies of local and systemic solicited reactions reported were consistent with those reported for the non-pregnant adult population during clinical studies conducted with Vaxigrip or Vaxigrip Tetra (QIV) even though higher for some adverse reactions (injection site pain, malaise, shivering, headache, myalgia).

Post marketing experience

Blood and lymphatic system disorders

Transient thrombocytopenia*, lymphadenopathy*

Immune system disorders

Allergic reactions including anaphylactic reactions, angioedema, shock, dyspnoea, urticaria, pruritus, rash erythematous

Nervous system disorders

Paraesthesia*, Guillain-Barré Syndrome (GBS), neuritis, neuralgia, convulsions, encephalomyelitis

Vascular disorders

Vasculitis, such as Henoch-Schönlein purpura, with transient renal involvement in certain cases.

* These adverse events were reported during clinical trials only in some age groups (see Section 4.8 Adverse effects (undesirable effects) – Clinical trial data).

Reporting suspected adverse effects

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 OVERDOSE

Cases of administration of more than the recommended dose (overdose) have been reported with Vaxigrip. When adverse reactions were reported, the information was consistent with the known safety profile of Vaxigrip described in Section 4.8 Adverse effects (undesirable effects).

For information on the management of overdose, contact the Poisons Information Centre, on 13 11 26 (Australia).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Influenza vaccine, ATC code: J07BB02

Mechanism of action

Vaxigrip provides active immunisation against three influenza virus strains (two A subtypes and one B type) contained in the vaccine.

Vaxigrip induces humoral antibodies against the haemagglutinins within 2 to 3 weeks. These antibodies neutralise influenza viruses.

Specific levels of haemagglutination-inhibition (HAI) antibody titre post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HAI antibody titres have been used as a measure of vaccine activity. In some human challenge studies, HAI antibody titres of $\geq 1:40$ have been associated with protection from influenza illness in up to 50% of subjects.

Since influenza viruses constantly evolve, the virus strains selected in the vaccine are reviewed annually by the WHO.

Annual influenza vaccination is recommended given the duration of immunity provided by the vaccine and because circulating strains of influenza virus change from year to year.

Clinical trials

Efficacy of Vaxigrip

Efficacy data for Vaxigrip are available in pregnant women and in infants less than 6 months of age born to vaccinated pregnant women (passive protection).

In children from 6 to 35 months of age and from 3 to 8 years of age (active immunisation) Vaxigrip efficacy is based on extrapolation of Vaxigrip Tetra (Quadrivalent Influenza Vaccine) efficacy.

No efficacy data are available for Vaxigrip in children and adolescents from 6 months to 17 years of age, in adults and in the elderly.

Children aged from 6 to 35 months (active immunisation)

A randomised placebo controlled study was conducted in 4 regions (Africa, Asia, Latina America and Europe) over 4 influenza seasons, in more than 5400 children from 6 to 35 months of age who received two doses (0.5 ml) of Vaxigrip Tetra (QIV) (N=2722), or placebo (NaCl 0.9%, N=2717) 28 days apart to assess Vaxigrip Tetra (QIV) efficacy for the prevention of laboratory confirmed influenza illness caused by any strain A and/or B and caused by vaccine similar strains (as determined by sequencing).

Laboratory-confirmed influenza illness was defined as influenza like-illness (ILI) [occurrence of fever $\geq 38^{\circ}\text{C}$ (that lasts at least 24 hours) concurrently with at least one of the following symptoms: cough, nasal congestion, rhinorrhoea, pharyngitis, otitis, vomiting, or diarrhoea] laboratory-confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) and/or viral culture.

Table 7 - Influenza attack rates and Vaxigrip Tetra (QIV) efficacy against laboratory-confirmed influenza illness in children from 6 to 35 months of age

	Vaxigrip Tetra (QIV) (N=2584)		Placebo (N=2591)		Efficacy
	n	Influenza attack rate (%)	n	Influenza attack rate (%)	% (2-sided 95% CI)
Laboratory-confirmed influenza illness caused by:					
Any influenza A or B Type	122	4.72	255	9.84	52.03 (40.24, 61.66)
Viral strains similar to those contained in the vaccine	26	1.01	85	3.28	69.33 (51.93; 81.03)

N=Number of children analysed (full set)

n=number of subjects fulfilling the item listed

CI=confidence interval

In addition, a predefined complementary analysis showed Vaxigrip Tetra (QIV) prevented 56.6% (95% CI: 37.0; 70.5) of severe laboratory-confirmed influenza illnesses due to any strain, and 71.7% (95% CI: 43.7; 86.9) of severe laboratory-confirmed influenza illnesses due to vaccine-similar strains. Furthermore, subjects receiving Vaxigrip Tetra (QIV) were 59.2% (95% CI: 44.4; 70.4) less likely to experience a medically attended influenza illness than subjects receiving placebo.

Severe laboratory-confirmed influenza illnesses were defined as ILI laboratory-confirmed by RT-PCR and/or viral culture with at least one of the following items:

- fever $> 39.5^{\circ}\text{C}$ for subjects aged < 24 months or $\geq 39.0^{\circ}\text{C}$ for subjects aged ≥ 24 months,
- and/or at least one significant ILI symptom which prevents daily activity (cough, nasal congestion, rhinorrhoea, pharyngitis, otitis, vomiting, diarrhoea),

- and/or one of the following events: acute otitis media, acute lower respiratory infection (pneumonia, bronchiolitis, bronchitis, croup), inpatient hospitalisation.

Children from 3 to 8 years of age (active immunisation)

Based on immune responses observed in children 3 to 8 years of age, the efficacy of Vaxigrip Tetra (QIV) in this population is expected to be at least similar to the efficacy observed in children from 6 to 35 months (see “Children from 6 to 35 months of age” above and “Immunogenicity of Vaxigrip Tetra” below).

Pregnant women

In the randomised, controlled, phase IV, clinical studies conducted in Mali, Nepal, and South Africa, approximately 5,000 pregnant women received Vaxigrip and approximately 5,000 pregnant women received placebo or control vaccine (quadrivalent meningococcal conjugate vaccine) during the second or third trimester of pregnancy. Vaccine efficacy against laboratory-confirmed influenza in pregnant women was evaluated as a secondary endpoint in all three studies.

The studies conducted in Mali and South Africa demonstrated the efficacy of Vaxigrip for the prevention of influenza in pregnant women (during pregnancy and for approximately 6 months post-delivery), following vaccination during these trimesters of pregnancy.

In the study conducted in Nepal, the efficacy of Vaxigrip for the prevention of influenza in pregnant women following vaccination during these trimesters of pregnancy was not demonstrated.

Table 8 - Influenza Attack Rates and Vaxigrip Efficacy against Laboratory-confirmed influenza in pregnant women

	Influenza Attack Rate (Any influenza A or B type) % (n/N)		Vaxigrip Efficacy % (95% CI)
	TIV	Control*	
Mali	0.5 (11/2,108)	1.9 (40/2,085)	70.3 (42.2 to 85.8)
	TIV	Placebo	
South Africa	1.8 (19/1,062)	3.6 (38/1,054)	50.4 (14.5 to 71.2)

* Meningococcal vaccine

N: Number of pregnant women included in analysis

n: number of subjects with laboratory confirmed influenza

CI: Confidence Interval

Infants younger than 6 months of age born to vaccinated pregnant women (passive protection)

Infants younger than 6 months of age are at high risk of influenza, resulting in high rates of hospitalization; however, influenza vaccines are not indicated for use in this age group.

Efficacy in infants younger than 6 months of age whose mothers received a single 0.5-ml dose of Vaxigrip during the second or third trimester has been demonstrated in clinical trials in Nepal, Mali and South Africa. Efficacy of Vaxigrip in infants younger than 6 months of age whose mothers were vaccinated during the first trimester has not been studied in these trials. Nevertheless, influenza vaccination during the first trimester should not be postponed (see Section 4.6 Fertility, pregnancy and lactation).

Table 9 - Influenza Attack Rates and Vaxigrip Efficacy against Laboratory-confirmed influenza in infants following vaccination in pregnant women

	Influenza Attack Rate (Any influenza A or B type) % (n/N)		Vaxigrip Efficacy % (95% CI)
	TIV	Control*	
Mali	2.4 (45/1,866)	3.8 (71/1,869)	37.3 (7.6 to 57.8)
	TIV	Placebo	
Nepal	4.1 (74/1,820)	5.8 (105/1,826)	30.0 (5 to 48)
South Africa	1.9 (19/1,026)	3.6 (37/1,023)	48.8 (11.6 to 70.4)

* Meningococcal vaccine

N: Number of infants included in the analysis

n: number of subjects with laboratory-confirmed influenza

CI: Confidence Interval

The efficacy data indicate a waning of protection in infants born to vaccinated mothers over time after birth.

In the trial conducted in South Africa, vaccine efficacy was highest among infants 8 weeks of age or younger (85.8% [95% CI, 38.3 to 98.4]) and decreased over time; vaccine efficacy was 25.5% (95% CI, -67.9 to 67.8) for infants >8 to 16 weeks of age and 30.4% (95% CI, -154.9 to 82.6) for infants >16 to 24 weeks of age.

In the trial conducted in Mali, there is also a trend of higher efficacy of Vaxigrip in infants during the first 4 months after birth (70.2% [95% CI, 35.7 to 87.6]), with lower efficacy within the fifth month of surveillance (60.7% [95% CI, 33.8 to 77.5]) and a marked fall within the sixth month (37.3% [95% CI, 7.6 to 57.8]).

The prevention of influenza disease can only be expected if the infant(s) are exposed to strains included in the vaccine administered to the mother.

Immunogenicity of Vaxigrip

Clinical studies performed in adults from 18 to 60 years of age, in elderly over 60 years of age, in children from 3 to 8 years of age and from 6 to 35 months of age assessed the non-inferiority of Vaxigrip versus Vaxigrip Tetra (QIV) for HAI (hemagglutinin inhibition) Geometric Mean antibody Titre (GMT) at Day 21 (for adults) and at Day 28 (for children), HAI seroconversion rate (4-fold rise in reciprocal titre or change from undetectable [< 10] to a reciprocal titre of ≥ 40), and HAI GMTR (post-/pre-vaccination titres).

One clinical study performed in adults from 18 to 60 years of age and in children from 9 to 17 years of age described the immune response of Vaxigrip versus Vaxigrip Tetra (QIV) for HAI GMT at Day 21. Another clinical study performed in children from 9 to 17 years of age described only the immune response of Vaxigrip Tetra (QIV).

One clinical study performed in pregnant women described the immune response of Vaxigrip and Vaxigrip Tetra (QIV) for HAI GMT at Day 21, HAI seroconversion rate, and HAI GMTR after one dose administered during the second or third trimester of pregnancy. In this study, the transplacental transfer was evaluated using HAI GMTs of maternal blood, of cord blood and of ratio cord blood/maternal blood, at delivery.

Vaxigrip induced a significant immune response to the 3 influenza strains contained in the vaccine.

Adults and elderly

A randomised, active controlled non-inferiority study was conducted to assess the immunogenicity of Vaxigrip Tetra (QIV) compared to Vaxigrip. A total of 1114 adults from 18 to 60 years of age and 1111 elderly over 60 years of age were randomised to receive either one dose of Vaxigrip (one of two formulations), each containing a B strain that corresponds to one of the two B strains in Vaxigrip Tetra (QIV) (a B strain of the Yamagata lineage and a B strain of the Victoria lineage) or one dose of Vaxigrip Tetra (QIV).

The immunogenicity of Vaxigrip and Vaxigrip Tetra (QIV) were assessed 21 days after injection by HAI method in all subjects (278 adults from 18 to 60 years of age for Vaxigrip, 832 adults from 18 to 60 years of age for Vaxigrip Tetra (QIV) and 275 adults over 60 years of age for Vaxigrip, 831 for Vaxigrip Tetra (QIV)) and by seroneutralisation (SN) method in subsets of subjects (100 adults from 18 to 60 years of age for Vaxigrip, 150 for Vaxigrip Tetra (QIV) and 98 adults over 60 years of age, 150 for Vaxigrip Tetra (QIV)).

Immunogenicity results in adults from 18 to 60 years of age and in elderly over 60 years of age for Vaxigrip are presented in [Table 10](#), [Table 11](#), [Table 12](#) and [Table 13](#) respectively.

Table 10 - Immunogenicity results by HAI method in adults from 18 to 60 years, 21 days post-vaccination with Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=140	TIV ^(b) (B Yamagata) N=138	QIV N=832
GMT (95% CI)			
A (H1N1) ^{(c)(d)}	685 (587; 800)		608 (563;657)
A (H3N2) ^(c)	629 (543; 728)		498 (459; 541)
B (Victoria)	735 (615; 879)	-	708 (661; 760)
B (Yamagata)	-	1735 (1490; 2019)	1715 (1607; 1830)
SC % (95% CI) ^(e)			
A (H1N1) ^{(c)(d)}	65.1 (59.2; 70.7)		64.1 (60.7; 67.4)
A (H3N2) ^(c)	73.4 (67.8; 78.5)		66.2 (62.9; 69.4)
B (Victoria)	70.0 (61.7; 77.4)	-	70.9 (67.7; 74.0)
B (Yamagata)	-	60.9 (52.2; 69.1)	63.7 (60.3;67.0)
GMTR (95% CI) ^(f)			
A (H1N1) ^{(c)(d)}	10.3 (8.35; 12.7)		9.77 (8.69; 11.0)
A (H3N2) ^(c)	14.9 (12.1; 18.4)		10.3 (9.15; 11.5)
B (Victoria)	11.4 (8.66; 15.0)	-	11.6 (10.4; 12.9)
B (Yamagata)	-	6.08 (4.79; 7.72)	7.35 (6.66;8.12)

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval

(a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)

(b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)

(c) Pooled TIV group includes participants vaccinated with either Alternative TIV or licensed TIV, N=278

(d) N=832 for QIV group

(e) SC: Seroconversion or significant increase: for subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer

(f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Table 11 - Immunogenicity results by SN method in adults from 18 to 60 years of age, 21 days post-vaccination with Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=50	TIV ^(b) (B Yamagata) N=50	QIV N=150
GMT (95% CI)			
A (H1N1) ^{(c)(d)}	3076 (2308; 4100)		3540 (2997; 4183)
A (H3N2) ^(c)	307 (239; 395)		215 (182; 254)
B (Victoria)	1269 (875; 1841)	-	1143 (952; 1373)
B (Yamagata)	-	1680 (1164; 2423)	1825 (1463; 2277)

Antigen Strain	TIV ^(a) (B Victoria) N=50	TIV ^(b) (B Yamagata) N=50	QIV N=150
	≥4-fold-rise n(%) ^(e)		
A (H1N1) ^{(c)(d)}	62.0 (51.7; 71.5)		61.3 (53.0; 69.2)
A (H3N2) ^(c)	59.0 (48.7; 68.7)		47.3 (39.1; 55.6)
B (Victoria)	66.0 (51.2; 78.8)	-	70.0 (62.0; 77.2)
B (Yamagata)	-	68.0 (53.3; 80.5)	67.3 (59.2; 74.8)
		GMTR (95% CI) ^(f)	
A (H1N1) ^{(c)(d)}	12.9 (8.89; 18.8)		13.4 (9.61; 18.6)
A (H3N2) ^(c)	7.01 (5.29; 9.30)		4.6 (3.81; 5.56)
B (Victoria)	11.4 (7.08; 18.3)	-	11.9 (9.24; 15.2)
B (Yamagata)	-	8.95 (5.96; 13.4)	12.8 (9.64; 17.0)

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer

- (a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)
- (b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)
- (c) Pooled TIV group includes participants vaccinated with either alternative TIV or licensed TIV, N=100
- (d) N=150 for QIV group
- (e) For subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Table 12 - Immunogenicity results by SN method in elderly over 60 years of age, 21 days post-vaccination with Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=138	TIV ^(b) (B Yamagata) N=137	QIV N=831
	GMT (95% CI)		
A (H1N1) ^{(c)(d)}	268 (228; 314)		219 (199; 241)
A (H3N2) ^(c)	410 (352; 476)		359 (329; 391)
B (Victoria)	301 (244; 372)	-	287 (265; 311)
B (Yamagata)	-	697 (593; 820)	655 (611; 701)
		SC % (95% CI) ^(e)	
A (H1N1) ^{(c)(d)}	50.2 (44.1; 56.2)		45.6 (42.1; 49.0)
A (H3N2) ^(c)	48.5 (42.5; 54.6)		47.5 (44.1; 51.0)
B (Victoria)	43.5 (35.1; 52.2)	-	45.2 (41.8; 48.7)
B (Yamagata)	-	38.7 (30.5; 47.4)	42.7 (39.3; 46.2)
		GMTR (95% CI) ^(f)	
A (H1N1) ^{(c)(d)}	6.03 (4.93; 7.37)		4.94 (4.46; 5.47)

Antigen Strain	TIV ^(a) (B Victoria) N=138	TIV ^(b) (B Yamagata) N=137	QIV N=831
A (H3N2) ^(c)	5.79 (4.74; 7.06)		5.60 (5.02; 6.24)
B (Victoria)	4.60 (3.50; 6.05)	-	4.61 (4.18; 5.09)
B (Yamagata)	-	4.11 (3.19; 5.30)	4.11 (3.73; 4.52)

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval

(a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)

(b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)

(c) Pooled TIV group includes participants vaccinated with either alternative TIV or licensed TIV, N=275

(d) N=832 for QIV group

(e) SC: Seroconversion or significant increase: for subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer

(f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Table 13 - Immunogenicity results by SN method in elderly over 60 years of age, 21 days post-vaccination with Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=49	TIV ^(b) (B Yamagata) N=49	QIV N=150
GMT (95% CI)			
A (H1N1) ^{(c)(d)}	1196 (902; 1584)		988 (763; 1279)
A (H3N2) ^(c)	192 (149; 246)		179 (151; 212)
B (Victoria)	559 (391; 799)	-	509 (414; 625)
B (Yamagata)	-	523(370; 738)	572 (465; 704)
≥4-fold-rise n(%) ^(e)			
A (H1N1) ^{(c)(d)}	52.0 (41.7; 62.2)		54.7(46.3; 62.8)
A (H3N2) ^(c)	34.7 (25.4; 45.0)		33.3 (25.9; 41.5)
B (Victoria)	36.7 (23.4; 51.7)	-	42.7 (34.6; 51.0)
B (Yamagata)	-	34.7 (21.7; 49.6)	41.6 (33.6; 50.0)
GMTR (95% CI) ^(f)			
A (H1N1) ^{(c)(d)}	7.76 (5.38; 11.2)		7.19 (5.59; 9.24)
A (H3N2) ^(c)	3.28 (2.57; 4.17)		3.67 (3.00; 4.50)
B (Victoria)	5.14 (3.34; 7.93)	-	4.46 (3.60; 5.53)
B (Yamagata)	-	3.84 (2.57; 5.74)	4.68 (3.67; 5.96)

Antigen Strain	TIV ^(a) (B Victoria) N=49	TIV ^(b) (B Yamagata) N=49	QIV N=150
N: number of subjects with available data for the considered endpoint			
GMT: Geometric Mean Titer			
(a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)			
(b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)			
(c) Pooled TIV group includes participants vaccinated with either alternative TIV or licensed TIV, N=98			
(d) N=150 for QIV group			
(e) For subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥ four-fold increase from pre- to post-vaccination titer			
(f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)			

The same trend as that described using HAI method was observed using SN method for both adult and elderly population.

Pregnant women and transplacental transfer

In a randomised, controlled clinical study conducted in Finland, a total of 116 pregnant women received Vaxigrip and 230 pregnant women received Vaxigrip Tetra (QIV) during the second or third trimester of pregnancy (from 20 to 32 weeks of pregnancy).

Immunogenicity results by HAI method, in pregnant women 21 days after vaccination with Vaxigrip or Vaxigrip Tetra (QIV) are presented in [Table 14](#).

Table 14 - Immunogenicity results by HAI method in pregnant women, 21 days post-vaccination with Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV (B Victoria) N=109	QIV N=216
GMT (95% CI)		
A (H1N1)*	638 (529; 769)	525 (466; 592)
A (H3N2)*	369 (283; 483)	341 (286; 407)
B1 (Victoria)*	697 (569; 855)	568 (496; 651)
B2 (Yamagata)*	-	993 (870; 1134)
≥4-fold-rise n (%) ^(a)		
A (H1N1)*	41.3 (31.9; 51.1)	38.0 (31.5; 44.8)
A (H3N2)*	62.4 (52.6; 71.5)	59.3 (52.4; 65.9)
B1 (Victoria)*	60.6 (50.7; 69.8)	61.1 (54.3; 67.7)
B2 (Yamagata)*	-	59.7 (52.9; 66.3)
GMTR (95% CI) ^(b)		
A (H1N1)*	5.26 (3.66; 7.55)	3.81 (3.11; 4.66)

Antigen Strain	TIV (B Victoria) N=109	QIV N=216
A (H3N2)*	9.23 (6.56; 13.0)	8.63 (6.85; 10.9)
B1 (Victoria)*	9.62 (6.89; 13.4)	8.48 (6.81; 10.6)
B2 (Yamagata)*	-	6.26 (5.12; 7.65)

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval

*A/H1N1: A/Michigan/45/2015 (H1N1) pdm09-like virus; A/H3N2: A/Hong Kong/4801/2014 (H3N2)-like virus;

B1: B/Brisbane/60/2008-like virus (B/Victoria lineage): *this strain was included in the TIV composition*;

B2: B/Phuket/3073/2013-like virus (B/Yamagata lineage): *this strain was not included in the TIV composition*.

- (a) SC: Seroconversion or significant increase: for subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (b) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Immunogenicity descriptive assessment by HAI method, at delivery, in blood sample of mother (BL03M), in cord blood sample (BL03B) and of the transplacental transfer (BL03B/ BL03M) are presented in **Table 15**.

Table 15 - Immunogenicity descriptive assessment by HAI method of Vaxigrip or Vaxigrip Tetra (QIV) at delivery

Antigen Strain	TIV (B Victoria) N=89	QIV N=178
	BL03M (Maternal blood) GMT (95% CI)	
A (H1N1)*	411 (332; 507)	304 (265; 349)
A (H3N2)*	186 (137; 250)	178 (146; 218)
B1 (Victoria)*	371 (299; 461)	290 (247; 341)
B2 (Yamagata)*	-	547 (463; 646)
	BL03B (Cord blood) GMT (95% CI)	
A (H1N1)*	751 (605; 932)	576 (492; 675)
A (H3N2)*	324 (232; 452)	305 (246; 379)
B1 (Victoria)*	608 (479; 772)	444 (372; 530)
B2 (Yamagata)*	-	921 (772; 1099)
	Transplacental transfer: BL03B/BL03M** GMT (95% CI)	
A (H1N1)*	1.83 (1.64; 2.04)	1.89 (1.72; 2.08)
A (H3N2)*	1.75 (1.55; 1.97)	1.71 (1.56; 1.87)
B1 (Victoria)*	1.64 (1.46 ; 1.85)	1.53 (1.37; 1.71)
B2 (Yamagata)*	-	1.69 (1.54; 1.85)

Antigen Strain	TIV (B Victoria) N=89	QIV N=178
----------------	-----------------------------	--------------

N: number of subjects with available data for the considered endpoint: women who received QIV or TIV, delivered at least 2 weeks after injection and with available cord blood and mother blood at the time of delivery.

GMT: Geometric Mean Titer; CI: Confidence Interval

*A/H1N1: A/Michigan/45/2015 (H1N1) pdm09-like virus; A/H3N2: A/Hong Kong/4801/2014 (H3N2)-like virus;

B1: B/Brisbane/60/2008-like virus (B/Victoria lineage): this strain was included in the TIV composition;

B2: B/Phuket/3073/2013-like virus (B/Yamagata lineage): this strain was not included in the TIV composition.

†BL03M: Blood sample of mother at delivery

**BL03B: Cord blood sample at delivery

§ If a mother have X babies, her titers values is counted X times

At delivery, the level of antibodies in the cord sample compared to the mother sample was almost doubled for the A/H1N1 strain and increased between 1.5 and 1.7 times for the A/H3N2, B/Victoria, and B/Yamagata strains, supporting that there is transplacental antibody transfer from mother to the newborn, following vaccination of women with Vaxigrip or Vaxigrip Tetra (QIV) during the second or third trimester of pregnancy.

These data are consistent with the passive protection demonstrated in infants from birth to approximately 6 months of age following vaccination of women during the second or third trimester of pregnancy with Vaxigrip in studies conducted in Mali, Nepal, and South Africa.

Children from 3 to 8 years of age:

A randomised, active controlled study was conducted to assess the immunogenicity of Vaxigrip compared to Vaxigrip Tetra (QIV). A total of 1242 children 3 to 8 years of age were randomised to receive either one or two doses of Vaxigrip or of Vaxigrip Tetra (QIV) depending on their previous influenza vaccination history.

The immunogenicity of Vaxigrip and Vaxigrip Tetra (QIV) were assessed 28 days after receipt of the last injection of Vaxigrip Tetra by HAI method in all subjects and by SN method in subsets of subjects.

Children who received a one-or two-dose schedule of Vaxigrip or Vaxigrip Tetra (QIV) presented a similar immune response following the last dose of the respective schedule.

Table 16 - Immunogenicity results by HAI method in children from 3 to 8 years of age, 28 days after the last injection of Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=176	TIV ^(b) (B Yamagata) N=168	QIV N=863
GMT (95% CI)			
A (H1N1) ^(c)	1141 (1006; 1295)		971 (896; 1052)
A (H3N2) ^(c)	1746 (1551; 1964)		1568 (1451; 1695)
B (Victoria) ^(d)	1120 (921; 1361)	-	1050 (956; 1154)

Antigen Strain	TIV ^(a) (B Victoria) N=176	TIV ^(b) (B Yamagata) N=168	QIV N=863
B (Yamagata) ^{(e)(f)}	-	1211 (1003; 1462) SC % (95% CI) ^(g)	1173 (1078; 1276)
A (H1N1) ^(c)		65.7 (60.4; 70.7)	65.7 (62.4; 68.9)
A (H3N2) ^(c)		67.7 (62.5; 72.6)	64.8 (61.5; 68.0)
B (Victoria) ^(d)	90.3 (85.0; 94.3)	-	84.8 (82.3; 87.2)
B (Yamagata) ^{(e)(f)}	-	89.9 (84.3; 94.0) GMTR (95% CI) ^(h)	88.5 (86.2; 90.6)
A (H1N1) ^(c)		7.65 (6.54; 8.95)	6.86 (6.24; 7.53)
A (H3N2) ^(c)		7.61 (6.69; 9.05)	7.49 (6.72; 8.35)
B (Victoria) ^(d)	17.8 (14.5; 22.0)	-	17.1 (15.5; 18.8)
B (Yamagata) ^{(e)(f)}	-	30.4 (23.8; 38.4)	25.3 (22.8; 28.2)

N=number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval

- (a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)
- (b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)
- (c) Pooled TIV group includes participants vaccinated with either alternative TIV or licensed TIV, N=344
- (d) N=169 for TIV (B Yamagata) group
- (e) N=862 for QIV group
- (f) N=175 for Vaxigrip (B Victoria) group
- (g) SC: Seroconversion or significant increase: for subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (h) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Table 17 - Immunogenicity results by SN method in children from 3 to 8 years of age, 28 days after the last injection of Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=86	TIV ^(b) (B Yamagata) N=83	QIV N=431
GMT (95% CI)			
A (H1N1) ^{(c)(d)}	4462 (3778; 5268)		3499 (3138; 3902)
A (H3N2) ^(c)	542 (467; 629)		475 (430; 525)
B (Victoria)	980 (722; 1329)	-	905 (788; 1039)
B (Yamagata)	-	952(709; 1279)	731 (638; 838)
≥4-fold-rise n(%) ^(e)			
A (H1N1) ^{(c)(d)}	60.9 (53.2; 68.3)		60.3(55.5; 65.0)
A (H3N2) ^(c)	52.1 (44.3; 59.8)		52.0 (47.1; 56.8)
B (Victoria)	89.5 (81.1; 95.1)	-	80.3 (76.2; 83.9)

Antigen Strain	TIV ^(a) (B Victoria) N=86	TIV ^(b) (B Yamagata) N=83	QIV N=431
B (Yamagata)	-	86.7 (77.5; 93.2) GMT (95% CI) ^(f)	84.7 (80.9; 88.0)
A (H1N1) ^{(c)(d)}		8.21 (6.37; 10.6)	8.45 (7.20; 9.92)
A (H3N2) ^(c)		5.45 (4.50; 6.61)	5.03 (4.46; 5.68)
B (Victoria)	15.6 (12.1; 20.1)	-	13.6 (11.9; 15.5)
B (Yamagata)	-	25.2 (18.1; 35.1)	19.3 (16.8; 22.1)

*: 28 days for primed subjects and 56 days for unprimed subjects

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer

- (a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)
- (b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)
- (c) Pooled TIV group includes participants vaccinated with either alternative TIV or licensed TIV, N=169
- (d) N=431 for QIV group
- (e) For subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

Children from 9 to 17 years of age:

In a total of 55 children from 9 to 17 years of age who received one dose of Vaxigrip and 429 children from 9 to 17 years of age who received one dose of Vaxigrip Tetra (QIV) the immune response against the strains contained in the vaccine was similar to the immune response induced in adults 18 to 60 years of age.

Children from 6 months to 35 months of age:

In addition to the Vaxigrip Tetra (QIV) efficacy, the immunogenicity of two 0.5 ml of doses of Vaxigrip (N=369) compared to two 0.5ml of doses of Vaxigrip Tetra QIV (N=341) was assessed 28 days after receipt of the last injection of Vaxigrip Tetra (QIV) by HAI method in children 6 to 35 months of age and by SN method in subsets of subjects.

Table 18 - Immunogenicity results by HAI method in children from 6 to 35 months of age, 28 days after the last injection of Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=172	TIV ^{(b) (c)} (B Yamagata) N=178	QIV N=341
GMT (95% CI)			
A (H1N1)	637 (500; 812)	628 (504; 781)	641 (547; 752)
A (H3N2)	1021 (824; 1266)	994 (807; 1224)	1071 (925; 1241)
B (Victoria)	835 (691; 1008)	-	623 (550; 706)

Antigen Strain	TIV ^(a) (B Victoria) N=172	TIV ^{(b) (c)} (B Yamagata) N=178	QIV N=341
B (Yamagata) ^(d)	-	1009 (850; 1198)	1010 (885; 1153)
		SC % (95% CI) (e)	
A (H1N1)	87.2 (81.3; 91.8)	90.4 (85.1; 94.3)	90.3 (86.7; 93.2)
A (H3N2)	88.4 (82.6; 92.8)	87.6 (81.9; 92.1)	90.3 (86.7; 93.2)
B (Victoria)	99.4 (96.8; 100.0)	-	98.8 (97.0; 99.7)
B (Yamagata)	-	99.4 (96.9; 100.0)	96.8 (94.3; 98.4)
		GMTR (95% CI) ^(f)	
A (H1N1)	35.3 (27.4; 45.5)	40.6 (32.6; 50.5)	36.6 (30.8; 43.6)
A (H3N2)	44.1 (33.1; 58.7)	37.1 (28.3; 48.6)	42.6 (35.1; 51.7)
B (Victoria)	114 (94.4; 138)	-	100 (88.9; 114)
B (Yamagata)	-	111 (91.3; 135)	93.9 (79.5; 111)

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer; CI: Confidence Interval

- (a) Alternative Vaxigrip containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)
- (b) 2014-2015 licensed Vaxigrip containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)
- (c) Dose of 0.5 ml
- (d) N=171 for Alternate Vaxigrip (B Victoria) group
- (e) SC: Seroconversion or significant increase: for subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (f) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

These immunogenicity data provide supportive information in addition to vaccine efficacy data available in this population.

Table 19 - Immunogenicity results by SN method in children from 6 to 35 months of age, 28 days after the last injection of Vaxigrip or Vaxigrip Tetra (QIV)

Antigen Strain	TIV ^(a) (B Victoria) N=86	TIV ^(b) (B Yamagata) N=88	QIV N=169
	GMT (95% CI)		
A (H1N1) ^(c)	2824 (2142; 3723)	2280 (1725; 3013)	2207 (1767; 2756)
A (H3N2)	574 (441; 748)	643 (491; 841)	516 (432; 617)
B (Victoria)	907 (690; 1191)	-	494 (415; 587)
B (Yamagata)	-	440 (334; 579)	371 (308; 447)
	≥4-fold-rise n(%) ^(d)		
A (H1N1) ^(c)	72.6 (61.8; 81.8)	84.1 (74.8; 91.0)	77.5 (70.5; 83.6)
A (H3N2)	78.8 (68.6; 86.9)	84.1 (74.8; 91.0)	84.6 (78.3; 89.7)

Antigen Strain	TIV ^(a) (B Victoria) N=86	TIV ^(b) (B Yamagata) N=88	QIV N=169
B (Victoria)	98.8 (93.6; 100.0)	-	98.2 (94.9; 99.6)
B (Yamagata)	-	95.5 (88.8; 98.7)	97.0 (93.2; 99.0)
GMTR (95% CI) ^(e)			
A (H1N1) ^(c)	70.7 (40.1; 125)	96.6 (59.3; 157)	73.3 (50.0; 108)
A (H3N2)	12.8 (9.36; 17.4)	16.5 (11.9; 22.7)	16.1 (12.9; 20.1)
B (Victoria)	98.3 (73.4; 132)	-	66.8 (55.7; 80.1)
B (Yamagata)	-	54.1 (41.4; 70.7)	44.4 (36.5; 53.9)

^{*}: 28 days for primed subjects and 56 days for unprimed subjects

N: number of subjects with available data for the considered endpoint

GMT: Geometric Mean Titer

- (a) Alternative TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Brisbane/60/2008 (Victoria lineage)
- (b) 2014-2015 licensed TIV containing A/California/7/2009 (H1N1), A/Texas/50/2012 (H3N2), and B/Massachusetts/2/2012 (Yamagata lineage)
- (c) N=85 for alternate TIV
- (d) For subjects with a pre-vaccination titer <10 (1/dil), proportion of subjects with a post-vaccination titer ≥40 (1/dil) and for subjects with a pre-vaccination titer ≥10 (1/dil), proportion of subjects with a ≥four-fold increase from pre- to post-vaccination titer
- (e) GMTR: Geometric mean of individual titer ratios (post-/pre-vaccination titers)

5.2 PHARMACOKINETIC PROPERTIES

No pharmacokinetic studies have been performed.

5.3 PRECLINICAL SAFETY DATA

Genotoxicity

Vaxigrip has not been tested for genotoxic potential

Carcinogenicity

Vaxigrip has not been tested for carcinogenic potential

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Buffer Solution:

- Sodium chloride

- Potassium chloride
- Dibasic sodium phosphate dihydrate
- Monobasic Potassium phosphate
- Water for injections

No adjuvant and no preservative are added.

Vaxigrip may contain traces of ovalbumin (≤ 0.05 micrograms), neomycin (≤ 10.1 picograms), formaldehyde (≤ 30 micrograms) and octoxinol-9 (≤ 222.5 micrograms), which are used during the manufacturing process (see Section 4.4 Special warnings and precautions for use).

6.2 INCOMPATIBILITIES

This vaccine must not be mixed with other vaccines or medicinal products.

6.3 SHELF LIFE

Vaxigrip has a shelf life of 12 months when stored at 2°C to 8°C.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store at 2°C to 8°C (Refrigerate. Do not freeze). Discard if vaccine has been frozen. In the absence of photostability studies, this vaccine should be protected from light.

6.5 NATURE AND CONTENTS OF CONTAINER

0.5 mL of suspension in pre-filled syringe with or without separate needle— pack size of 1 or 10*.

Vaxigrip pre-filled syringe is not made with natural rubber latex.

*Not all pack sizes or presentations may be marketed.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

After use, any remaining vaccine and container must be disposed of safely, preferably by heat inactivation or incineration, according to locally agreed procedures.

6.7 PHYSICOCHEMICAL PROPERTIES

Chemical structure and CAS number

Not applicable/defined for vaccines.

7 MEDICINE SCHEDULE (POISONS STANDARD)

S4 – Prescription Only Medicine

8 SPONSOR

sanofi-aventis australia pty ltd
12 – 24 Talavera Road
Macquarie Park NSW 2113
Australia
Freecall: 1800 818 806
Email: medinfo.australia@sanofi.com

9 DATE OF FIRST APPROVAL

05 November 2025

10 DATE OF REVISION

03 December 2025

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
2	Annual Strain Update